Emory School of Medicine
Death receptor 5 (DR5) is a cell surface receptor and can initiate apoptosis upon overexpression or binding to its ligand (TRAIL). Accordingly, apoptosis-inducing DR5 agonistic antibodies have been developed and are being tested in the clinic. Ras (e.g., H-Ras or K-Ras) and B-Raf (i.e., V600E) mutations are common oncogenic events in human cancers, primarily through activation of the ERK/RSK signaling cascade. Interestingly, we have recently demonstrated that these mutations induce DR5 expression and the cancer cell lines with these mutations tend to be highly sensitive to a DR5 agonistic antibody.
My research interest is revealing the molecular mechanisms of DR5 involved in not only apoptotic mechanism, but also in non-apoptotic functions (e.g., oncogenic and metastatic process). Thus, my research goal focuses on the biological role of DR5 in cancer and its impact on DR5-targeted cancer therapy.
View publications on PubMed